A conceptual parallel exists where RBCK1 promotes resistance to the tyrosine kinase inhibitor sunitinib in clear cell renal cell carcinoma (Wang et al., 2023), further validating its potential as a treatment-refractory biomarker. The gene discussed is RBCK1; the disease is clear cell renal carcinoma.